GEN Exclusives

More »

GEN News Highlights

More »
Aug 21, 2013

Appetite-Controlling Hormone Leaves Obese People Still Hungry

  • Researchers report that although glucagon loses its ability to help obese people feel full after a meal, it continues to suppress hunger pangs in people with type 1 diabetes. The team’s findings will be published in the Journal of Clinical Endocrinology & Metabolism.

    The primary role of glucagon, a hormone secreted by the pancreas, is to signal the body to release stored glucose when blood sugar falls too low. But growing evidence suggests the hormone also may play a role in controlling food intake and feelings of fullness through signaling the body to reduce levels of other appetite hormones like ghrelin.

    “Once a person becomes obese, glucagon no longer induces feelings of fullness,” explained the study’s lead author, Ayman M. Arafat, M.D., of Charité-University of Medicine in Berlin. “Further research is needed to determine why glucagon no longer suppresses appetite effectively in this population, even though they are otherwise healthy.”

    The prospective, double-blinded, placebo-controlled study investigated glucagon levels and appetite among 11 obese people, 13 people with type 1 diabetes, and 13 lean people. Participants received injections of either glucagon or a placebo. Researchers then measured participants’ appetites using a satiety scale as well as levels of the appetite hormone ghrelin.

    Feelings of fullness did not differ between obese study participants who received glucagon injections and those who were given the placebo. In comparison, participants who were lean or had type 1 diabetes reported feeling significantly more full after receiving glucagon. The response to the hormone was detectable in this population, even 24 hours after it was administered.

    “The findings could influence efforts to develop new treatments for obesity and diabetes,” continued Dr. Arafat. “Although therapeutic agents that influence glucagon and other hormones currently are considered a promising avenue for research, this study suggests a treatment involving glucagon may be ineffective in controlling meal size in people who are obese.”

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »